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HIGHLIGHTS
• Self‑oxygenation/degradable nanozyme reactors with core–shell structure were fabricated for relieving tumor hypoxia.
• Intratumoral hypoxia alleviation and sensitization of immunochemotherapy using as‑prepared nanozyme reactors was demonstrated 
in B16F10 melanoma tumor.
ABSTRACT Recently emerged cancer immunochemotherapy has provided enormous new possibilities to replace traditional chemotherapy 
in fighting tumor. However, the treatment efficacy is hampered by tumor hypoxia‑
induced immunosuppression in tumor microenvironment (TME). Herein, we 
fabricated a self‑oxygenation/degradable inorganic nanozyme with a core–shell 
structure to relieve tumor hypoxia in cancer immunochemotherapy. By inte‑
grating the biocompatible  CaO2 as the oxygen‑storing component, this strategy 
is more effective than the earlier designed nanocarriers for delivering oxygen 
or  H2O2, and thus provides remarkable oxygenation and long‑term capability 
in relieving hypoxia throughout the tumor tissue. Consequently, in vivo tests 
validate that the delivery system can successfully relieve hypoxia and reverse 
the immunosuppressive TME to favor antitumor immune responses, leading to 
enhanced chemoimmunotherapy with cytotoxic T lymphocyte‑associated antigen 
4 blockade. Overall, a facile, robust and effective strategy is proposed to improve 
tumor oxygenation by using self‑decomposable and biocompatible inorganic 
nanozyme reactor, which will not only provide an innovative pathway to relieve 
intratumoral hypoxia, but also present potential applications in other oxygen‑favored cancer therapies or oxygen deficiency‑originated 
diseases.
KEYWORDS Inorganic nanozyme; Self‑oxygenation nanoreactor; Biodegradable nanomedicine; Immunochemotherapy; Cancer 
treatment
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1 Introduction
Cancer immunochemotherapy that integrates chemothera‑
peutic and immune‑modulating agents has attracted increas‑
ing attentions due to the synergistically enhanced antitumor 
effects [1]. However, the development of immunochemo‑
therapy is hampered by the lack of a nanoplatform that can 
effectively and simultaneously achieve both therapeutic 
goals in tumor tissues [2]. In the emerging immunochemo‑
therapy for cancer treatment, it is often encountered that the 
immune system fails to respond to the tumor cells [3], even 
when a large number of antitumor T cells are present [4]. It 
has been clear that the TME, featured with low pH values, 
insufficient blood flow, overproduced peroxide and hypoxia, 
plays a vital role in such failures for tumor immunosuppres‑
sion [5–7]. Among these characteristics, the hypoxia has 
been reported as one of the most unfavorable features that 
tend to suppress the immunotherapeutic efficiency [8–10]. In 
many in vivo situations, the activation and effector function 
of antitumor T cells can be diminished in the hypoxic TME, 
which thus protect tumor cells from being eliminated via 
immune system [11]. A dominant pathway in such immu‑
nosuppression is the hypoxia‑adenosinergic signaling [12], 
because of which the immune‑cell function will be nega‑
tively regulated, the production of effector cytokines such 
as interferon‑γ (IFN‑γ) will be reduced and inhibitors of 
this signaling such as A2AR antagonist and extracellular 
adenosine‑degrading drugs have been used as adjuvant to 
compromise the hypoxia‑induced tumor protection. Hence, 
modulating the unfavorable hypoxia characteristic of TME 
has been considered as an effective and clinically valuable 
strategy for improving tumor immunotherapy [13, 14].
To overcome the tumor hypoxia‑induced immunosup‑
pression, different strategies have been proposed recently to 
enhance the tumor oxygenation, for instance by increasing 
the intratumoral blood flow via normalization of tumor vas‑
culatures [15], or using perfluorocarbon to deliver oxygen 
to hypoxic tumor tissue [16]. A direct and robust approach 
proposed by Sitkovsky’s group was to provide supplemen‑
tary oxygen, in which tumor‑bearing mice were placed in 
chambers containing 60% oxygen for respiratory hyperoxia 
[17–19]. This treatment effectively weakened hypoxia and 
alleviated immunosuppression, resulting in strong tumor 
rejection [18, 19]. Meanwhile, it has been proved that the 
tumor cells can produce excessive amounts of  H2O2 within 
the TME by the overexpressed superoxide dismutase [20], 
which thus has been utilized for producing  O2 to relieve 
the tumor hypoxia [21]. The development of nanotechnol‑
ogy offers new opportunities to address the shortcomings of 
conventional designs [22–28]; inorganic nanomaterials with 
catalase mimetic properties, such as the  MnO2 and carbon 
nitride‑based nanostructures, have been designed to generate 
oxygen in tumor tissue [29–35]. However, the concentration 
of endogenous  H2O2 is extremely low, generally reported to 
be 50–100 × 10−6 M, [20, 36] which is too low to generate 
sufficient amount of oxygen for inducing satisfactory tumor 
hypoxia relief [20]. Very recently, the tumor oxygenation by 
delivering exogenous  H2O2 and the subsequent catalase‑trig‑
gered  H2O2 decomposition/oxygen generation has been pro‑
posed to offer a more effective approach for tumor oxygena‑
tion [37]. However, direct delivery of  H2O2 via liposomes or 
 H2O2‑related particles possess several intrinsic drawbacks, 
such as difficulty in preparation and storage, relatively low 
stability after injection, and hard to control the releasing 
speed of  H2O2 and maintain the activity of catalase, which 
will undoubtedly hamper its practical application for tumor 
hypoxia. Therefore, fabricating more robust and facile alter‑
native with enhanced physiological stability and lowered 
cost is highly desirable and necessary.
Herein, we report a self‑oxygenation/degradable inorganic 
nanozyme reactor (NR) that can effectively relieve tumor 
hypoxia for sensitized cancer immunochemotherapy. The 
core of nanozyme reactor is composed of  CaO2/doxorubicin 
(DOX), and the shell consists of degradable  SiO2/DOX‑
MnO2; thus, this whole nanoplatform is named as  CaO2/
DOX@SiO2/DOX‑MnO2 (CDSDM) NR.  CaO2 can be grad‑
ually hydrolyzed to generate  H2O2, which as the “fuel” can 
diffuse through the shell and decompose in the presence of 
 MnO2 to produce oxygen. Meanwhile, the embedded DOX 
in  CaO2 core and  SiO2 shell allows efficient chemotherapy 
and also facilitates the self‑decomposition of the resulting 
 SiO2/DOX structure. Compared with nanoparticles without 
 CaO2 core that can only decompose the tumor endogenous 
 H2O2, the  CaO2 core‑contained CDSDM NR provides much 
remarkable oxygenation and long‑term capability in reliev‑
ing hypoxia throughout the tumor tissue.
In vivo tests also validate that treatment with these 
CDSDM NRs can efficiently relieve hypoxia in B16F10 
melanoma tumor model, thus reversing the immunosup‑
pressive TME to favor antitumor immunities. By combin‑
ing cytotoxic T lymphocyte‑associated antigen 4 (CTLA‑4) 
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blockade‑mediated immunotherapy with CDSDM NR treat‑
ment, strong tumor regression was observed. Further studies 
reveal that CDSDM NR treatment can enhance the intratu‑
moral infiltration of antitumor  CD8+ T cells and decrease the 
population of immunosuppressive regulatory T cells (Tregs). 
Moreover, it has been noticed that these CDSDM NRs show 
no obvious toxicity. Therefore, our TME‑motivated self‑oxy‑
genation/degradable inorganic nanozyme reactor not only 
provides an innovative and facile tumor oxygenation strategy 
to relieve tumor hypoxia, but also holds great potential in 
other oxygen‑favored therapies and oxygen deficiency‑orig‑
inated diseases, as well as in anti‑pathogen treatments [38].
2  Experimental
2.1  Synthesis of CSDM and CDSDM NRs
Preparation of  CaO2 and  CaO2/DOX cores: The method 
was derived from the gas diffusion‑controlled preparation 
of  CaCO3 NPs. Typically, 50 mg of  CaCl2·2H2O was dis‑
solved in 50 mL of ethanol in a beaker, into which 0.2 mL 
of 30%  H2O2 solution was added. The beaker was then cov‑
ered by parafilm with a few holes and left in a desiccator 
at 35 °C together with a glass bottle containing 2 mL of 
ammonia. After 2 h of reaction, white colloid was obtained 
in the beaker. The product was centrifuged and washed with 
ethanol for further use. For preparation of  CaO2/DOX cores, 
5 mg of doxorubicin hydrochloride (DOX·HCl, 98%) was 
added into the solution containing  CaCl2 and  H2O2 before 
incubating with ammonia.
Encapsulation of self‑decomposable  SiO2/DOX shell: 
4 mL of about 2.5 mg mL−1 of  CaO2 core or  CaO2/DOX 
solution was dissolved into 50 mL absolute ethanol, and 
then 15 mg of polyvinyl pyrrolidone (PVP, MW ~ 58,000, 
k29–32) was added. Under stirring, 30 μL of 2 M NaOH 
solution and 15 mg of DOX·HCl are sequentially added. 
0.1 mL of tetraethyl orthosilicate (TEOS, 99.99%) was then 
added. After 24 h of reaction in dark, the solution was cen‑
trifuged at 8000 rpm and washed with water three times and 
dispersed in water for further use.
Preparation and adsorption of CSDM and CDSDM NRs: 
Ultra‑small  MnO2 nanodots were first prepared according 
to previous reports with certain modification [30]. Briefly, 
70 mg of  KMnO4 (≥ 99.5%) and 55 mg of poly(allylamine 
hydrochloride) (PAH, MW ~ 15,000, 98%) were separately 
dissolved into 10 mL of deionized water. Under stirring, the 
 KMnO4 solution was added dropwise into the PAH solu‑
tion. After 15 min of reaction, 0.75 mL of pH 6.5 phosphate 
buffer saline (PBS) was added to 10 mL of the brown solu‑
tion to disturb the stabilization by PAH. The obtained mix‑
ture was centrifuged at 10,000 rpm for 5 min and washed 
with water. 5 mL of about 1 mg mL−1 of  SiO2/DOX shell‑
encapsulated NP solution was mixed with 0.2 mL of about 
0.5 mg mL−1  MnO2 nanodot solution under stirring, and 
CDSDM or CSDM NRs were obtained via charge attraction.
2.2  Characterizations
UV–Vis spectrophotometer (Shimadzu UV‑2550) and flu‑
orescence spectrophotometer (Edinburgh FS5) were used 
to obtain absorption and photoluminescence (PL) spectra, 
respectively. Transmission electron microscope (TEM) 
images were taken using a HT7700 (Hitachi) transmission 
electron microscope. Selected area diffraction and elemental 
mapping were acquired using a JEM 2100 (JEOL) transmis‑
sion electron microscope. X‑ray photoelectron spectrometry 
(XPS) assay was performed using a PHI 5000 VersaProbe 
(UIVAC‑PHI, Japan) spectrometer.
2.3  Oxygen Generation and DOX Release
Oxygen generation by NRs was detected based on the 
decrease in fluorescence intensity of tris(4,7‑diphenyl‑
1,10‑phenanthroline) ruthenium dichloride (Ru(dpp)3Cl2, 
98%) in the presence of oxygen. Under  N2 atmosphere, 
CDSDM NRs (~ 2 mg mL−1) were mixed with ethanolic 
solution of Ru(dpp)3Cl2 (40 μM) and incubated for different 
durations. At scheduled time points, the solution was centri‑
fuged (8000 rpm, 3 min) and the supernatant was subjected 
to fluorescence detection with the tube sealed. CDSDM NR 
solution without Ru(dpp)3Cl2 was independently tested to 
exclude the influence of DOX fluorescence. DOX release 
from CDSDM NRs was measured by dialyzing with filter 
of 1000 Da cut‑off. For in vitro hypoxia level evaluation, 
B16F10 cells were cultured for 4 h in 0.5 L rectangular 
jar sealed with a pouch, and then 0.2 mL of PBS, hDSDM 
(1.2 mg mL−1) or CDSDM (2.5 mg mL−1) NRs was added, 
followed by pimonidazole. After 4 h of incubation, cells 
were washed and FITC‑conjugated anti‑pimonidazole 
(Hypoxyprobe) was added and further co‑incubated for 1 h. 
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Cell imaging was performed with a laser confocal scanning 
microscope (LCSM, Olympus Fluoview 1000).
2.4  Evaluation of In Vivo NR Distribution
In vivo imaging and histological section imaging were per‑
formed to study the in vivo NR distribution. For in vivo 
imaging, CDSDM NRs were intravenously injected into 
B16F10 tumor‑bearing mice. IVIS In Vivo Imaging Sys‑
tem (PerkinElmer) was used to monitor the NR distri‑
bution in a mouse based on the fluorescence of DOX 
(λex/λex = 500/610 nm). After different time post‑injection, 
mice were sacrificed and major organs and tumor were col‑
lected for imaging and then sliced into sections for histologi‑
cal imaging using LCSM. All in vivo experiments involving 
mice were approved by the Jiangsu Association for Labora‑
tory Animals and the Department of Science and Technol‑
ogy of Jiangsu Province.
2.5  Evaluation of Intratumoral Hypoxia
Balb/c mice with established B16F10 tumors were intra‑
venously injected with saline, hDSDM NPs (0.2 mL of 
1.2 mg mL−1) or CDSDM NRs (0.2 mL of 2.5 mg mL−1). 
Hypoxyprobe‑1 Green kit was used to detect hypoxia. Eight‑
hour post‑injection, pimonidazole (2 mg per mouse) was 
intravenously injected. 1 h later, tumors were dissected 
and cryo‑sectioned, which were then co‑incubated with 
anti‑pimonidazole antibody. Cell nuclei were stained using 
4′,6‑diamidino‑2‑phenylindole (DAPI). Photoacoustic imag‑
ing and 3D cell culture model were also employed for the 
evaluation of hypoxia relief. Endra Nexus 128 PA imag‑
ing system was used for photoacoustic imaging, which was 
based on the different peak absorptions of oxyhemoglobin 
(~ 850 nm) and deoxyhemoglobin (~ 760 nm). Mice were 
kept anaesthetized so that the same section of each tumor 
tissue (about 3 mm from tumor surface) could be imaged 
for better comparison. Imaging was performed at 760 and 
850 nm at each time point within 2 h. Three‑dimensional 
tumor spheroids (400–500 μm, from KeyGen Co. Ltd., Nan‑
jing) were co‑incubated with different agents for 6 h, and 
pimonidazole hydrochloride was then added for another two 
of co‑incubation. Then spheroids were cryo‑sectioned and 
sequentially stained with anti‑pimonidazole antibody and 
DAPI.
2.6  Detection of Extracellular Adenosine and Cytokines
Tumor tissues excised after different treatments were firstly 
digested into single‑cell suspensions. Erythro‑9‑(2‑hydroxy‑
3‑nonyl) adenine was added into the filtrates to prevent the 
degradation of adenosine. The resulting mixture was then 
centrifuged at 10,000 rpm for 10 min. The supernatants were 
then filtered with a 3000 Da cut‑off filter, and the filtrate 
was freeze‑dried and re‑dissolved by water of 1/100 of ini‑
tial volume. Adenosine measurement was carried out using 
high‑performance liquid chromatography (Agilent 1260) 
(mobile phases: methanol and 10 mM  KH2PO4, v/v of 1/9). 
For cytokine detection, serum samples were obtained from 
mice after above treatments, and mouse interferon γ (IFN‑
γ, Elabscience) and mouse tumor necrosis factor α (TNF‑α, 
Elabscience) Elisa kits were used.
2.7  Antitumor Treatment with NRs and CTLA‑4 
Blockade
Mice with established B16F10 tumors (~ 60 mm3) were 
randomly divided into five groups. The closely monitored 
treatment period is 20 days, during which mice were treated 
with saline, or saline and CTLA‑4 blockade, or CSDM 
NRs, or CDSDM NRs, or hDSDM NPs and CTLA‑4 block‑
ade, or CDSDM NRs and CTLA‑4 blockade, or CDSDM 
NRs + CSDM NRs (adaptive administration) and CTLA‑4 
blockade. In adaptive administration, CDSDM NRs were 
given firstly, which was replaced by CSDM NRs if tumor 
size reduced by 10% or more compared to the last meas‑
urement; CDSDM NRs would not be reused until tumor 
size increased at least 10% compared to the last measure‑
ment. Tumor size was calculated based on the formula: 
 width2 × length/2. Saline, NPs (0.2 mL of 1.2 mg mL−1) 
and NRs (0.2 mL of 2.5 mg mL−1) were given every 2 days, 
while CTLA‑4 blockade (20 μL) was given every 4 days. 
During the treatment, the tumor volume, body weight and 
body condition (mobility, food taking, palpable infection, 
etc.) were closely monitored.
2.8  Western Blot
Mice with established B16F10 tumor were administrated 
with saline, hDSDM NRs (0.2 mL of 1.2 mg mL−1) or 
CDSDM NRs (0.2 mL of 2.5 mg mL−1). 24 h later, the 
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tumors were excised and digested, and the single‑cell sus‑
pensions were put through a 70 μm strainer. Cells were fur‑
ther digested in lysis buffer containing proteinase inhibitor. 
Lysates were centrifuged at 10,000 rpm for 5 min at 4 °C to 
collect the supernatant. Protein concentration was analyzed 
via BCA protein assay reagent. After separation with 12% 
SDS‑PAGE, the proteins were transferred to nitrocellulose 
membrane. After further incubation with 5% nonfat milk 
powder solution, membrane was incubated with primary 
antibodies including anti‑mouse CD39 and anti‑mouse 
CD73 (Santa Cruz) overnight, and horseradish peroxidase‑
conjugated secondary antibodies were then incubated for 
1 h. Enhanced chemiluminescence reagent was used to visu‑
alize the bands.
2.9  Immunofluorescence Staining
Tumor tissues excised after 4 days of the indicated treat‑
ments in main text were embedded by OCT compound and 
sectioned into 10 μm slices. Shallow tissue was defined as 
about 0–1.5 mm from surface, while deep tissue was > 2 mm 
from surface. (The average diameter of tumor was about 
4–6 mm.) After fixed with acetone/methanol (1/1 in v:v), 
FITC‑conjugated anti‑HIF‑α and Alexa680‑conjugated anti‑
CD8 antibodies (Santa Cruz) at a concentration of 1:100 
were used for staining. Excitation of CD8 antibodies was 
carefully filtered to avoid the interference of DOX fluores‑
cence. DAPI was used for staining nuclei.
2.10  Flow Cytometry
For analysis of HIF‑1α expression, tumor tissues were 
excised from mice after different treatments and homog‑
enized with Collagenase D in 1640 cell culture media at 
37 °C. The obtained single‑cell suspensions were washed 
and fixed with Fix/Perm, and anti‑HIF‑1α‑FITC (Santa 
Cruz) was co‑incubated for 20 min in dark. For the analysis 
of intratumoral Tregs, the single‑cell suspensions from dif‑
ferent groups were filtered with 70 μm strainer and washed, 
and anti‑CD25‑Alexa Fluor 790 (Santa Cruz), anti‑CD4‑
FITC (Santa Cruz) and anti‑Foxp3‑Alexa Fluor 680 (Santa 
Cruz) were used for surface staining in dark. For analysis of 
the maturation of DCs, two peripheral lymph nodes under 
the armpit at tumor side were isolated, and the obtained 
single‑cell suspensions were stained with anti‑CD80‑FITC 
and anti‑CD60‑Alexa Fluor 680 (Santa Cruz) in dark. A BD 
FACSCalibur flow cytometer was used in flow cytometry.
2.11  Statistics
SPSS Statistics 19 was used for data analysis including 
standard deviation and significance test. Student’s t test was 
used for the comparison of volume or concentration statistics 
between the test group and each of other groups.
3  Results and Discussion
3.1  Synthesis and Properties of Oxygen‑Self‑Produced 
CDSDM NRs
The synthetic procedure of CDSDM NRs is illustrated in 
Fig. 1a; the core of NR is composed of self‑decomposable 
 CaO2/DOX, and the shell consists of biodegradable  SiO2/
DOX‑MnO2. DOX was incorporated into silica shells to 
enable the shell self‑decomposition, and was further embed‑
ded into  CaO2 cores to improve the DOX loading capacity. 
Particularly, the  CaO2 cores were prepared via a gas diffu‑
sion method (Fig. S1) and showed monodispersed spherical 
morphology (Fig. S2). High‑resolution transmission electron 
microscope (HRTEM) and selected area electron diffraction 
(SAED) results demonstrated the  CaO2 characteristic crys‑
talline. DOX could be readily incorporated into  CaO2 NPs 
due to the formation of Ca‑DOX complex, despite the more 
amorphous crystalline of the resulting produces. Unlike 
the previously reported  H2O2‑filled polymersome used for 
reactive oxygen species‑mediated therapy [39], here, the 
generation of  H2O2 (hydrolysis of  CaO2) was sustained and 
preferred in the acidic TME (pH ~ 6.5) and endosome (pH 
~ 5.5) (Fig. S3), favoring the constant and specific oxygen 
supply to tumor tissue.  CaO2 cores could not be dispersed 
in water, while the encapsulation of  SiO2 shell allowed the 
 CaO2 cores to be stably dispersed in aqueous media. Suc‑
cessful  SiO2 shell encapsulation needs to control the water 
concentration in the ethanol solution containing  CaO2 cores 
and tetraethyl orthosilicate (TEOS,  SiO2 precursor) because 
high water concentration would lead to aggregation of  CaO2 
cores. Hence, concentrated NaOH solution instead of ammo‑
nia was used to catalyze the TEOS hydrolysis. Incorpora‑
tion of DOX into shells was achieved by introducing DOX 
into the  SiO2 shell growth media. With the constant DOX 
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release, the shell would collapse and decompose into pieces 
that can be excreted via renal system [40, 41]. After the 
optimization of shell thickness (Fig. S4), a 15 nm shell was 
selected for the subsequent study.
Ultra‑small (~ 1.2 nm)  MnO2 nanodots were prepared 
according to the previous reports with certain modification 
(Fig. S5) [30], and were adsorbed onto the shells via charge 
attraction, after which the NR zeta potential increased from 

























































































Fig. 1  a Schematic illustration of the preparation of CDSDM NRs. For the control groups, the  CaO2@SiO2/DOX‑MnO2 is named as CSDM 
NRs; after completely hydrolyzing  CaO2 core in the CDSDM NRs, the hollow nanoparticle is named as hDSDM NPs. b Representative TEM 
image and c elemental mapping of CDSDM NRs. d UV–Vis absorption and photoluminescence spectra of CDSDM NRs. Insets are photographs 
of CDSDM NRs taken under (left) room light or (right) 365 nm light irradiation. e Zeta Potential of  MnO2 nanodots,  CaO2/DOX@SiO2/DOX 
NPs and CDSDM NRs
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efficacy of  MnO2 toward  H2O2, the adsorbed amount of 
 MnO2 nanodots was limited to this extent to ensure the 
resulting NRs could be readily dispersed in water without 
flocculation in at least 24 h (Fig. S6). The resulting CDSDM 
NRs were about 125 nm in diameter (Fig. 1b). Energy‑dis‑
persive X‑ray spectroscopy (EDS) mapping (Fig. 1c) shows 
the expected elements including Ca (from  CaO2 cores), 
Si (from  SiO2 shells), O (from cores and shells), N (from 
DOX) and Mn (from  MnO2 nanodots). UV–Vis absorp‑
tion and photoluminescence spectra (Figs. 1d, S7) show the 
DOX characteristic absorption and luminescence properties 
of CDSDM NRs. X‑ray photoelectron spectroscopy (XPS) 
pattern (Fig. S8) also detected these elements, in which the 
relative weak Ca signal was ascribed to the limited detec‑
tion depth of XPS (less than 10 nm) than the typical shell 
thickness (15 nm), and further demonstrated the core/shell 
structure of the CDSDM NRs. The Ca/Si/Mn ratio in NRs 
measured using inductively coupled plasma optical emission 
spectrometry (ICP‑OES) was about 1:0.91:0.1. Zeta poten‑
tial of NRs in water is shown in Fig. 1e.
Incubating CDSDM NRs in phosphate buffer saline 
(PBS) led to the hydrolysis of  CaO2 into  H2O2, which dif‑
fused through the permeable  SiO2 shell and decomposed in 
the presence of  MnO2 nanodots to provide oxygen (Fig. 2a). 
The hydrolysis of  CaO2 cores was faster at lower pH (Fig. 
S3), thus facilitated the controlled oxygen supply in acidic 
TME and endosome, as shown in Fig. 2b. Incubating NRs 
in pH 5.5 PBS for about 4 h led to complete decomposition 
of cores, while the remained products were hollow nano‑
particles (Fig. 2c, denoted as hDSDM NPs) with about 48% 
of the weight of whole NRs. The similar zeta potential sug‑
gested that  MnO2 nanodots were basically retained in these 
hDSDM NPs. Due to the incorporation of DOX molecules, 
the cross‑linking degree of silica matrix (products of TEOS 
hydrolysis) would be lowered due to the steric effect of DOX 
molecules. In aqueous media where DOX is soluble, the 
constant release of DOX from the silica will trigger the silica 
shell disruption and finally lead to the complete fragmen‑
tation into poly(silicic acid) that can be excreted via renal 
system (Fig. 2c) [41].  MnO2 nanodots were also decomposed 
after about 24 h of incubation, in accordance with previous 
report [29]. The self‑decomposition capability of NRs was 
believed to be important for reducing systemic toxicity when 
used in vivo.
Incubating hypoxic B16F10 cells with CDSDM NRs 
for 4 h, the cellular hypoxia was effectively reconditioned 
(Fig. 2d) due to the constant oxygen supply by CDSDM 
NRs. In obvious comparison, the hDSDM NPs exhibited 
no such effect, suggesting the importance of  CaO2 cores 
in providing sufficient oxygen; CDSD  (CaO2/DOX@SiO2/
DOX) NP treatment also showed no obvious hypoxia relief, 
which should be due to the limited  H2O2 decomposition 
for oxygenation without  MnO2 nanodots. The cytoplasmic 
distribution of the main DOX fluorescence suggested that 
DOX might be trapped inside shells at the beginning despite 
the decomposition of  CaO2, because otherwise substantial 
DOX would be accumulated in nuclei. This was confirmed 
by analyzing the release profile via UV–Vis absorption 
measurement that the DOX release was lagged much behind 
the oxygen generation (Fig. 2b, e). Meanwhile, lower pH 
allowed faster DOX release. The DOX release from  SiO2 
shells was found to be more sustained by analyzing CSDM 
NRs (absorption spectra shown in Fig. S9) that contained 
no DOX in  CaO2 cores, in line with the lower decomposi‑
tion rate of  SiO2 shells than  CaO2 cores. In vitro antitumor 
capabilities of CDSDM NRs, CSDM NRs and hDSDM 
NPs were evaluated via MTT assay (Fig. S10). The results 
showed that CDSDM NRs exhibited significantly higher 
cytotoxicity than hDSDM NPs under hypoxic condition. 
This was ascribed to the sensitization of chemotherapy by 
oxygenation, which has become a widely explored strategy 
for improving therapeutic efficacy of chemo drugs.
3.2  Relief of Tumor Hypoxia and Suppression 
of Hypoxia‑Adenosinergic Signaling
Lower oxygen tension in solid tumor tissue can weaken 
the efficacy of spontaneous or adoptive immunotherapy, 
in which the hypoxia‑adenosinergic signaling has been 
known as a master pathway [12]. In this work, the capa‑
bility of CDSDM NRs in reversing such immunosuppres‑
sion was tested. In vivo distribution of CDSDM NRs when 
intravenously injected into mice‑bearing B16F10 mela‑
noma tumor under armpit was first studied. By monitoring 
the fluorescence signal of DOX, substantial intratumoral 
accumulation was observed 8‑h post‑injection (Fig. 3a) 
owing to the enhanced permeability and retention effect 
of tumor vasculature [42]. Similar results were observed 
from ex vivo imaging of excised organs and microscopic 
imaging of histological sections (Figs. 3a, S11). Quan‑
titative analysis using inductively coupled plasma mass 
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Fig. 2  a Schematic illustration of the processes of oxygen generation, DOX release and decomposition of NRs. b The measurement of oxygen 
release process of CDSDM NRs, shown as the ratio of fluorescence intensity of Ru(dpp)3Cl2 (an oxygen indicator) after incubated with NRs for 
different durations (I) to that before incubation (I0). c TEM images of the decomposition process of CDSDM NRs after incubated in pH 5.5 PBS 
for different durations. d Representative CLSM images of B16F10 cells from hypoxia cultivation after co‑incubated with (1) PBS, (2) hDSDM 
NPs, (3) CDSD (without  MnO2 nanodots) NPs and (4) CDSDM NRs for 4 h. Hypoxia level was detected using Hypoxyprobe. e DOX release 
from CDSDM NRs and CSDM NRs in PBS of different pH values
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spectrometry (ICP‑MS) showed up to 23% of Si accu‑
mulation in tumor 8‑h post‑injection (Fig. S12). Next, 
intratumoral hypoxia level was evaluated using hypoxia 
marker Hypoxyprobe. As shown in Fig. 3b, the intratu‑
moral hypoxia was clearly alleviated even after one dose 
of CDSDM NR administration, in contrast to hDSDM NP 
treatment. Three‑dimensional cell culture model (Fig. S13) 
and photoacoustic imaging (Fig. S14) were also employed 
to validate the hypoxia alleviation, and the results provided 
further demonstration of the superior hypoxia‑relieving 
capability of CDSDM NRs than hDSDM NPs. Although 
the  MnO2 nanodots on hDSDM NPs can catalyze the 
decomposition of  H2O2, which is relatively abundant in 
tumor tissue [29, 43], they seem to be much less efficient 
in alleviating tumor hypoxia, further underscoring the 
necessity of  CaO2 cores in this work.
Next, the effect of CDSDM NR treatment on hypoxia‑
adenosinergic signaling was studied. Expressions of several 
key molecular events of the signaling including hypoxia‑
inducible factor‑1α (HIF‑1α), CD39/CD73 and adenosine 
were tested. Flow cytometry and western blot results showed 
that treatment with CDSDM NRs resulted in significantly 
reduced expression of HIF‑1α in cells from tumor tissue 
(Fig. 3c) and CD39/CD73 in T cells (Fig. 3d), respectively, 
compared with the hDSDM group. HIF‑1α is the master 
regulator of hypoxic response in T cells, while the CD39/
CD73 expression can be lowered by HIF‑1α reduction [44, 
45]; these should be ascribable to the reduced CD39/CD73 
expression in T cells by hypoxia relief. HIF‑1α can be rap‑
idly degraded under normal conditions via being poly‑ubiq‑
uitinated, while hypoxia (oxygen tension lower than about 
3%) can drive the enzyme‑mediating HIF‑1α degradation 
nonfunctional [46]. Therefore, the reduced HIF‑1α was 
also a further demonstration of the relief of hypoxia. The 
extracellular adenosine in TME also significantly decreased 
largely as a consequence of the reduced expression of adeno‑
sine generating CD39/CD73 (Fig. 3e). Taken together, it can 
be concluded that the hypoxia‑adenosinergic signaling has 
been inhibited efficiently, through which a positive immune 
modulation can be expected via its effects on Tregs and cyto‑
toxic T cells (CTL) [12].
3.3  Strong Tumor Regression 
with Oxygen‑Self‑Generated CDSDM NRs
Given the effective inhibition of hypoxia‑adenosinergic 
signaling, one can expect a synergistic effect between NR 
treatment and immunotherapy. CTLA‑4 blockade, a FDA 
approved immune checkpoint‑blocking antibody for the 
treatment of advanced melanoma [47], was used for the erad‑
ication of B16F10 melanoma tumor in this work. To reduce 
the damage of DOX‑containing NRs to the immune system, 
CSDM NRs was also used for adaptive administration with 
CDSDM NRs (Fig. 4a). The DOX amount in CSDM NRs 
was about half of that in CDSDM NRs (Table S1). Adaptive 
administration here means adjusting the dosage of chemo‑
therapeutic drug according to the variation of tumor size 
rather than giving an invariable high dose in order to protect 
the immune system by chemo agent (DOX) [48, 49].
In this work, CDSDM NRs were given in initial treat‑
ment, while CSDM NRs would be used as alternatives if 
tumor volume decreased or increased less than 10% from the 
previous measurement; otherwise CDSDM NRs would be 
reused. In a 20‑day treatment period, different agents were 
intravenously injected every 2 days, while CTLA‑4 blocking 
antibody was injected intraperitoneally every 4 days. Tumor 
volume, body weight and survival rate in each group were 
monitored during and after treatment (Fig. 4b–d). Compared 
with the oxygen‑self‑produced CDSDM NRs + CTLA‑4 
blockade, the results showed that hDSDM NPs + CTLA‑4 
blockade showed much weaker antitumor efficacy (evaluated 
according to tumor volume, survival rate and histopathology 
staining of tumor tissue, Figs. 4b, d and S15, S16), although 
stronger than CTLA‑4 blockade alone. Therefore, relief of 
intratumoral hypoxia should be a prerequisite for CTLA‑4 
blockade to exert due antitumor efficacy, considering the 
same DOX concentration in hDSDM NPs and CDSDM 
NRs. Meanwhile, adaptive administration of CDSDM/
CSDM NRs showed stronger efficacy than the CDSDM 
NRs albeit the lower total DOX dose (Fig. S17), suggesting 
an immune benefit of this chemotherapy strategy [49]. In a 
control study using immune‑deficient nude mice, the syner‑
gistic effects between CDSDM NR and CTLA‑4 blockade 
treatment were much limited due to the attenuated cellular 
immunity (Fig. S19). Instead, the DOX in CDSDM NRs 
accounted for the observed antitumor efficacy. Therefore, it 
is believed that a complete immune system is a prerequisite 


































































































Fig. 3  a In vivo fluorescence monitoring of the distribution of CDSDM NRs in B16F10 tumor‑bearing mice at scheduled time points post‑
intravenous injection, and ex vivo fluorescence of major organs and tumor 8‑h post‑injection. b Fluorescence imaging of tumor tissue sections 
after receiving different treatments, in which signals include DOX fluorescence, Hypoxyprobe (hypoxia indicator) and DAPI. c Flow cytometric 
analysis of the intratumoral HIF‑1α level after different treatments. d Western blot results of the expressions of CD39 and CD73 on intratumoral 
T lymphocytes after 2 days of the indicated treatments. e Concentrations of extracellular adenosine in tumor tissue after 2 days of the indicated 
treatments. *P < 0.05; ***P < 0.001 versus the last group
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Fig. 4  a Illustration of adaptive administration of CDSDM NRs and CSDM NRs. b Relative tumor volumes and c body weights of B16F10 
tumor‑bearing mice received with different treatments during the treatment period. d Survival rate of mice in each group during and after treat‑
ment. Serum levels of e IFN‑γ and f TNF‑α detected after 8 days of different treatments. *P < 0.05; **P < 0.01; ***P < 0.001 versus Group 5
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for the sensitization of immunotherapy by CDSDM NR‑
induced hypoxia relief.
We also tested the immune effect in molecular level by 
measuring the production of typical cytokines. Measurement 
of the serum levels of IFN‑γ and TNF‑α (typical markers 
of cellular immune response) showed increased production 
in mice treated with CDSDM NRs than that with hDSDM 
NPs (Fig. 4e, f), which should be one of the results of the 
alleviation of hypoxia‑adenosinergic signaling and reflected 
a stronger antitumor immune response [50, 51]. Adaptive 
administration of CDSDM and CSDM NRs further induced 
slight increase in cytokine production due to the more potent 
immune system with reduced DOX dose.
Meanwhile, no obvious reduction in body weight was 
observed in mice treated with CDSDM/CSDM NRs 
(Fig. 4c), suggesting the indistinctive systemic toxicity. 
The body weight loss in mice in other three groups could 
be ascribed to reduced food intake and fat loss due to the 
increased tumor burden. Hematoxylin–eosin histopathology 
staining results also indicated the rather limited damage of 
major organs caused by CDSDM/CSDM NRs (Fig. S20). 
Hemolysis test was also performed by incubating CDSDM 
NRs with red blood cells, and the hemolysis induced by 
CDSDM NRs at the concentration for treatment was 
believed to be acceptable (Fig. S21). [52] Therefore, the as‑
prepared oxygen‑self‑produced CDSDM (and CSDM) NRs 
were considered to be a considerably safe hypoxia‑relieving 
nanoformulation.
3.4  Enhanced  CD8+ T Cell Infiltration and Suppressed 
Treg Development
Tregs can diminish spontaneous or blockade‑mediated anti‑
tumor immune responses via the expressions of CD39/CD73 
and constitutive CTLA‑4 [53]. The former could deliver neg‑
ative immunomodulation via hypoxia‑adenosinergic signal‑
ing, while the latter has made Treg a master target of the cur‑
rently widely studied CTLA‑4 blockade [47, 53]. It has been 
proposed that hypoxia alleviation by hyperoxia breathing 
could reduce the Treg population [19], and in this work, the 
effect of oxygen‑self‑produced NRs on Treg population was 
studied. Flow cytometric results showed that in comparison 
with hDSDM NPs, treatment with CDSDM or CSDM NRs 
resulted in a significant decrease (by a factor of ~ 4) in intra‑
tumoral Treg  (CD4+  CD25+  Foxp3+) population (Fig. 5a). In 
line with the superior tumor regression using CDSDM NRs 
than hDSDM NPs, this suggested that Treg‑related immu‑
nosuppression could be greatly alleviated in complementary 
manners with the inhibition of hypoxia‑adenosinergic sign‑
aling and the use of CTLA‑4 blockade (CTLA‑4 contributes 
to the immunosuppressive function of Tregs). Also, it can be 
expected to achieve synergistic effect when combining NRs 
with other blocking antibodies of immune checkpoints, for 
instance the PD‑1/PD‑L1 [54].
Antitumor T cells can be repelled in hypoxic areas, and 
this is why endogenous developed or adoptively transferred 
tumor‑responsive  CD8+ T cells showed limited antitumor 
efficacy and were often combined with other agents such 
as antagonist of adenosine receptor [55]. Inspired by the 
observation that the recruitment of  CD8+ T cells could be 
enhanced by respiratory hyperoxia [19], we tested whether 
the hypoxia relief with CDSDM NRs facilitated the intratu‑
moral infiltration of antitumor  CD8+ T cells. Tumor tissues 
from different groups were analyzed by the co‑staining of 
HIF‑1α and CD8, and the results suggested that in both shal‑
low (Fig. S22) and deep (Fig. 5b) tumor tissues, treatment 
with CDSDM NRs resulted in reduced HIF‑1α expression 
and enhanced intratumoral accumulation and infiltration 
of  CD8+ T cells. Therefore, hypoxia alleviation with our 
NRs could significantly reduce the repelling of CTLs (i.e., 
activated  CD8+ T cells) by tumor tissue, and as a desirable 
extension of the functions of CDSDM NR treatment, this 
was ascribed to another contribution to the enhanced tumor 
regression as shown in Fig. 4b.
The released DOX from CDSDM NRs, while serving as 
the typical chemo agent to induce apoptosis of tumor cells, 
was also found to be immunogenic. Incorporation of DOX 
into  SiO2 shells were designed to achieve immuno‑chemo‑
combined therapy and to enable the self‑decomposition of 
the  SiO2 shells; meanwhile, it has been reported that anthra‑
cyclines, in particular, DOX‑treated dying or apoptotic 
tumor cells can serve as in situ vaccine to induce immu‑
nogenic tumor cell death in the absence of any adjuvant or 
co‑stimulus [56, 57]. Therefore, we have explored the effect 
of DOX on immunogenicity by analyzing maturation of den‑
dritic cells (DCs), which can phagocytose the DOX‑treated 
apoptotic cells, present the neoantigens to T cells and mature 
during this process. DCs were isolated from axillary lymph 
nodes at tumor side after 4 days of different treatments, 
and flow cytometric results of the staining of CD80 and 
CD86 (typical markers of DC maturation) showed that the 
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Fig. 5  a Flow cytometry plots showing the percentages of intratumoral Treg (gated on  CD25+ T cells) populations from mice after 4 days of the 
indicated treatments. b Immunofluorescence results of the co‑staining of HIF‑1α and CD8 to deep (> 2 mm from the surface) tumor tissues from 
mice received 4 days of the indicated treatments. c Flow cytometry plots showing the percentages of  CD80+ and  CD86+ matured DCs (gated on 
CD11c+ DCs) from the axillary lymph nodes of mice after 4 days of the indicated treatments
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percentage of matured DCs was much higher in mice treated 
with hDSDM NPs or CDSDM NRs (Fig. 5c). The increase 
in median percentage in CSDM NR group was ascribed to 
the lower DOX concentration. Therefore, in current experi‑
mental setting, the DOX embedded in  SiO2 shells served not 
only as the chemotherapeutic drug but also a vaccine primer 
that led to a productive immune activation, together with 
CTLA‑4 blockade in a synergistic manner (CTLA‑4 block‑
ade can enhance the immunopermissive recognition between 
naive T cells and antigen‑presenting mature DCs) [58].
Based on the above observations, the schematic illustra‑
tion of the proposed roles of CDSDM NRs in tumor hypoxia 
relief is shown in Scheme 1a. Both the hydrolysis of  CaO2 
and the endogenous  H2O2 within tumor contributed the 
abundant oxygenation via the catalase‑like activity of  MnO2 
nanodots. The multiple roles of CDSDM NRs in tumor 
rejection are shown in Scheme 1b. Basically, the immuno‑
priming effects of CDSDM NRs were derived from their two 
capabilities, i.e., the TME‑motivated oxygen‑self‑produc‑



















































Scheme 1  a Schematic illustration of the proposed roles of CDSDM NRs in tumor hypoxia relief. b The proposed mechanism and reaction 
pathways include the relief of hypoxia‑induced immunosuppression (red dashed arrows), the DOX‑mediated chemotherapy and immune activa‑
tion (blue dotted arrows), and the synergistic actions between them and the CTLA‑4 blockade (green arrows). (Color figure online)
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NR decomposition. The former effectively relieved intratu‑
moral hypoxia, and the resulting immune benefits included: 
(1) the immunosuppressive hypoxia‑adenosinergic signaling 
was inhibited (Fig. 3b–e), and as a direct result, the produc‑
tion of antitumor cytokines (e.g., IFN‑γ and TNF‑α) by T 
lymphocytes increased (Fig. 4e, f). (2) The negative immu‑
nomodulation by Tregs was inhibited due to the decreased 
expression of CD39/CD73 (Fig. 3d) and the reduced popula‑
tion (Fig. 5a). These effects could promote the activation of 
antitumor immune responses in a complementary manner 
with the CTLA‑4 blockade. (Treg is a master expression 
host for CTLA‑4). (3) Due to the decreased hypoxic repel‑
ling effect, the intratumoral infiltration and accumulation of 
 CD8+ T cells were improved (Fig. 5b). The released DOX 
from CDSDM NRs, while serving as the typical chemo 
agent to induce apoptosis of tumor cells, was also found 
to be immunogenic by inducing DC maturation (Fig. 5c) 
and thereby promoting T cell activation synergistically with 
CTLA‑4 blockade. 
4  Conclusion
In summary, a self‑oxygenation/degradable inorganic 
nanozyme system has been fabricated to relieve tumor 
hypoxia for cancer immunochemotherapy. By integrating 
 CaO2 core as the oxygen‑storing component, our system 
provides improved oxygenation and capability of relieving 
hypoxia compared with the oxygenation methods that only 
decompose the endogenous  H2O2 in TME. Compared to 
the reported design that directly delivers  H2O2, our strategy 
shows acid TME‑preferred oxygenation and enhanced physi‑
ological stability. In vivo tests validated that the CDSDM 
NRs could successfully relieve hypoxia in mice‑bearing 
B16F10 tumor, thus reversing the immunosuppressive 
TME to favor antitumor immune response. Consequently, 
the CTLA‑4‑mediated immunotherapy was greatly sensi‑
tized. Further studies revealed that CDSDM NR treatment 
also enhanced the intratumoral infiltration of  CD8+ T cells 
and decreased the population of immunosuppressive Tregs. 
Meanwhile, the DOX in CDSDM NRs also elicited desirable 
maturation of DCs, further favored a productive antitumor 
immune response. Overall, a novel self‑oxygenation/degra‑
dable nanozyme system has been proposed to improve the 
cancer immunochemotherapy via relieving tumor hypoxia 
without causing notable toxic side effects. This strategy not 
only shows promise in relieving tumor hypoxia and sensitiz‑
ing cancer immunochemotherapy, but also holds the poten‑
tial for applications in oxygen‑favored cancer therapy (i.e., 
photodynamic and radiation therapy) and oxygen deficiency‑
originated diseases.
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